Sol-Gel Technologies Cash on Hand 2016-2024 | SLGL
Sol-Gel Technologies cash on hand from 2016 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Sol-Gel Technologies Annual Cash on Hand
(Millions of US $) |
| 2023 |
$28 |
| 2022 |
$21 |
| 2021 |
$22 |
| 2020 |
$29 |
| 2019 |
$50 |
| 2018 |
$62 |
| 2017 |
$5 |
| 2016 |
$7 |
| 2015 |
$6 |
Sol-Gel Technologies Quarterly Cash on Hand
(Millions of US $) |
| 2024-09-30 |
$28 |
| 2024-06-30 |
$26 |
| 2024-03-31 |
$28 |
| 2023-12-31 |
$28 |
| 2023-09-30 |
$31 |
| 2023-06-30 |
$33 |
| 2023-03-31 |
$25 |
| 2022-12-31 |
$21 |
| 2022-09-30 |
$18 |
| 2022-06-30 |
$16 |
| 2022-03-31 |
$27 |
| 2021-12-31 |
$22 |
| 2021-09-30 |
$46 |
| 2021-06-30 |
$18 |
| 2021-03-31 |
$25 |
| 2020-12-31 |
$29 |
| 2020-09-30 |
$36 |
| 2020-06-30 |
$46 |
| 2020-03-31 |
$48 |
| 2019-12-31 |
$50 |
| 2019-09-30 |
$58 |
| 2019-06-30 |
$50 |
| 2019-03-31 |
$53 |
| 2018-06-30 |
$78 |
| 2018-03-31 |
$80 |
| 2017-12-31 |
|
| 2017-09-30 |
$12 |
| 2017-06-30 |
|
| 2016-12-31 |
$7 |
| 2015-12-31 |
$6 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
